Published in N Engl J Med on June 07, 2009
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI2D) | NCT00006305
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) (VADT) | NCT00032487
Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease | NCT03700645
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med (2016) 4.52
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol (2013) 3.15
Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial†. Eur J Cardiothorac Surg (2015) 2.00
Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care (2009) 2.00
Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol (2011) 1.91
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care (2010) 1.78
Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation (2014) 1.68
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J (2013) 1.60
Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation (2010) 1.56
Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol (2013) 1.55
Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction: Insights From STICH. J Am Coll Cardiol (2015) 1.55
Computed fractional flow reserve (FFTCT) derived from coronary CT angiography. J Cardiovasc Transl Res (2013) 1.49
Coronary artery bypass in patients with type 2 diabetes: experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. J Thorac Cardiovasc Surg (2014) 1.47
Trends in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA (2013) 1.41
Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg (2014) 1.41
Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr (2017) 1.39
Stress Perfusion Cardiac Magnetic Resonance Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia. Circ Cardiovasc Imaging (2016) 1.37
Calcification in atherosclerosis. Nat Rev Cardiol (2009) 1.20
Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc (2013) 1.18
Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes. Diabetes Care (2013) 1.14
Impact of diabetes on cardiovascular disease: an update. Int J Hypertens (2013) 1.13
Diabetes with coronary disease--a moving target amid evolving therapies? N Engl J Med (2009) 1.12
Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2012) 1.09
Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr (2010) 1.05
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res (2012) 1.04
Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc (2012) 1.04
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2012) 1.04
Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care (2013) 1.01
Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc (2009) 1.00
Imaging of coronary atherosclerosis - evolution towards new treatment strategies. Nat Rev Cardiol (2016) 0.99
PAI-1 and diabetes: a journey from the bench to the bedside. Diabetes Care (2012) 0.99
Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study. Cardiovasc Diabetol (2011) 0.99
Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes (2014) 0.98
Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration. Diabetes (2011) 0.97
Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging (2014) 0.97
Imaging Atherosclerosis. Circ Res (2016) 0.95
Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) (2012) 0.95
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. Circ Cardiovasc Qual Outcomes (2012) 0.94
Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care (2011) 0.93
Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diabetes Care (2011) 0.93
Diabetes and coronary heart disease: a risk factor for the global epidemic. Int J Hypertens (2012) 0.91
Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry. Clin Res Cardiol (2010) 0.91
Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial. J Am Coll Cardiol (2015) 0.90
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention: a meta-analysis. Heart (2015) 0.90
Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep (2012) 0.90
Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from coronary revascularization. Circ Cardiovasc Imaging (2012) 0.90
Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90
Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta (2011) 0.90
Editorial on management of diabetes mellitus with coronary artery disease. Arch Med Sci (2011) 0.89
The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease. Diabetes Care (2013) 0.89
Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep (2012) 0.89
Coronary artery revascularization in patients with diabetes mellitus. Circulation (2013) 0.89
Diabetes and cardiovascular disease in older adults: current status and future directions. Diabetes (2014) 0.89
Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol (2013) 0.89
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. Cardiovasc Diabetol (2011) 0.88
Thiazolidinediones: a 2010 perspective. Perm J (2010) 0.88
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 0.87
Coronary revascularization in diabetic patients: Current state of evidence. Exp Clin Cardiol (2011) 0.87
HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol (2015) 0.86
Management standards for stable coronary artery disease in India. Indian Heart J (2016) 0.86
Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol (2009) 0.86
Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J Nucl Cardiol (2013) 0.85
Synergy between direct coronary stenting technique and use of the novel thin strut cobalt chromium Skylor™ stent: the MACE in follow up patients treated with Skylor stent [MILES Study]. Curr Cardiol Rev (2012) 0.85
Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep (2014) 0.85
Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol (2015) 0.84
The case for intervention bias in the practice of medicine. Yale J Biol Med (2013) 0.84
The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep (2011) 0.84
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Clinical review: Screening for coronary artery disease in type 2 diabetes. J Clin Endocrinol Metab (2012) 0.83
Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort. J Am Heart Assoc (2016) 0.83
Clinical implications of the BARI 2D and COURAGE trials: overview. Coron Artery Dis (2010) 0.83
Trends in postacute myocardial infarction management and mortality in patients with diabetes. A population-based study from 1995 to 2001. Can J Cardiol (2010) 0.83
Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc (2012) 0.83
Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. Cardiorenal Med (2012) 0.83
Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol (2013) 0.83
Chronic total occlusion: To treat or not to treat. World J Cardiol (2014) 0.82
Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care (2013) 0.82
Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity (Silver Spring) (2009) 0.82
Estimated insulin sensitivity predicts regression of albuminuria in Type 1 diabetes. Diabet Med (2014) 0.82
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol (2014) 0.81
Value of Exercise ECG for Risk Stratification in Suspected or Known CAD in the Era of Advanced Imaging Technologies. JACC Cardiovasc Imaging (2015) 0.81
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet (1994) 11.37
Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med (1996) 6.70
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol (2007) 4.04
Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 3.17
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet (2006) 3.01
Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet (2009) 2.81
Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet (1997) 2.47
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J (2008) 2.40
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest (2006) 2.40
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol (1998) 1.91
The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab (2004) 1.84
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
Modifications of coronary risk factors. Am J Cardiol (2006) 1.41
Effect of coronary bypass surgery on longevity in high and low risk patients. Report from the V.A. Cooperative Coronary Surgery Study. Lancet (1977) 1.39
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv (2009) 1.38
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 1.37
Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? Am Heart J (2001) 1.09
Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol (2002) 1.08
Factors influencing clinical outcomes after revascularization in the asymptomatic cardiac ischemia pilot (ACIP). ACIP Study Group. J Card Surg (2000) 1.06
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med (2011) 7.52
Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med (2005) 7.46
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA (2003) 7.01
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (2007) 5.74
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Nephropathy in diabetes. Diabetes Care (2004) 4.08
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. Ann Intern Med (2010) 3.45
Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA (2003) 3.33
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Association of coronary CT angiography or stress testing with subsequent utilization and spending among Medicare beneficiaries. JAMA (2011) 3.17
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA (2004) 3.17
Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med (2007) 3.10
Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation (2003) 3.01
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 2.95
Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA (2007) 2.93
Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med (2009) 2.88
Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med (2002) 2.87
Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation (2003) 2.80
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med (2014) 2.69
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J (2006) 2.67
Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation (2004) 2.67
Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). J Am Coll Cardiol (2012) 2.60
A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med (2008) 2.60
Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention. Diabetes Care (2006) 2.59
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
Impact of the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act on abdominal ultrasonography use among Medicare beneficiaries. Arch Intern Med (2012) 2.57
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) (2006) 2.56
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol (2007) 2.49
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Type 1 diabetes and coronary artery disease. Diabetes Care (2006) 2.47
Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol (2006) 2.40
Validation of a new brief physical activity survey among men and women aged 60-69 years. Am J Epidemiol (2006) 2.37
Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2002) 2.35
Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun (2007) 2.35
Coronary heart disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol (2003) 2.34
Advances in the treatment of prolactinomas. Endocr Rev (2006) 2.31
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation (2006) 2.24
Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation (2006) 2.24
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab (2012) 2.22
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol (2010) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17